What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 - Zacks

Retrieved on: 2024-12-26 14:40:13

Tags for this article:

Regenerative biomedicine

Mesoblast

Food and Drug Administration

Drug development

Click the tags to see associated articles and topics

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 - Zacks. View article details on hiswai:

Summary

The article discusses notable performances in the biotech sector, highlighting companies like Mesoblast, engaged in regenerative biomedicine. The FDA’s role in approving key therapies and ongoing drug development projects is emphasized, relating to AMD innovations.

Article found on: www.zacks.com

View Original Article